Replimune Group Inc.
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
IPO Year: 2018
Exchange: NASDAQ
Website: replimune.com
Recent Analyst Ratings for Replimune Group Inc.
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/28/2024 | $17.00 | Buy | ROTH MKM |
4/17/2023 | $44.00 | Overweight | Piper Sandler |
11/19/2021 | $52.00 | Overweight | Piper Sandler |
10/15/2021 | $60.00 | Buy | BTIG Research |
8/23/2021 | $55.00 → $49.00 | Outperform | SVB Leerink |
8/9/2021 | $56.00 → $55.00 | Outperform | SVB Leerink |
Replimune Group Inc. Press Releases
Fastest customizable press release news feed in the world
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WOBURN, Mass., March 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees. The Company granted equity awards to 10 employees as a material inducement to commencing their employment with the Company. The inducement awards consist of non-qualified stock options to purchase an aggregate of 11,085 shares of the Company's common stock and restricted stock units representing an aggregate of 22,225 shares of the Company's common stock. Each option has an exercise price of $12.29 per share, w
Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update
U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for priority review with a PDUFA date of July 22, 2025 IGNYTE-3 confirmatory trial of RP1(vusolimogene oderparepvec) plus nivolumab in advanced melanoma is enrolling Enrolled first patients in trials evaluating RP2 for the treatment of metastatic uveal melanoma and hepatocellular carcinoma WOBURN, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal third quarter ended Dec
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WOBURN, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees. The Company granted equity awards to 34 employees as a material inducement to commencing their employment with the Company. The inducement awards consist of non-qualified stock options to purchase an aggregate of 58,240 shares of the Company's common stock and restricted stock units representing an aggregate of 116,680 shares of the Company's common stock. Each option has an exercise price of $14.25 per share, w
Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma
WOBURN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for patients with advanced melanoma. The FDA granted the BLA Priority Review with a Prescription Drug User Fee Act (PDUFA) action date of July 22, 2025. The FDA also informed the Company that they are not currently planning to hold an advisory committee meeting in relation to this application, and at this time have not ident
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WOBURN, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees. The Company recently granted equity awards to 30 employees as a material inducement to commencing their employment with the Company. The inducement awards consist of non-qualified stock options to purchase an aggregate of 95,250 shares of the Company's common stock and restricted stock units representing an aggregate of 158,570 shares of the Company's common stock. The non-qualified stock options consist of gra
Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials
WOBURN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the first patients have been enrolled in studies evaluating RP2 in two different settings: checkpoint naïve metastatic uveal melanoma; and second-line recurrent or metastatic hepatocellular carcinoma (HCC). "On the heels of our BLA submission for RP1 and designation as breakthrough therapy, we are pleased that the first patients have been enrolled in both the RP2 HCC clinical trial and the registration intended study of RP2 in metastatic uveal melanoma," said Sushil Patel, Ph.D., CEO
Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference
WOBURN, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 2:15 PM PT. A simultaneous webcast will be available in the Investors section of Replimune's website at replimune.com. A replay will be available for 30 days following the conference. About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development
Replimune Announces Pricing of Upsized Public Offering
BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the pricing of its public offering of 6,923,000 shares of its common stock at a public offering price of $13.00 per share. In addition, in lieu of common stock to certain investors, Replimune today announced the pricing of its public offering of pre-funded warrants to purchase 3,846,184 shares of its common stock at a purchase price of $12.9999 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.0001 per share exercise price of each pre-funded
Replimune Announces Proposed Public Offering
WOBURN, Mass., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced a proposed public offering of $125 million of shares of its common stock and pre-funded warrants to purchase shares of common stock. All securities in the offering will be offered by Replimune. In addition, Replimune intends to grant the underwriter a 30-day option to purchase up to an additional $18.75 million of securities from Replimune at the public offering price, less the underwriting discounts and commissions. Leerink Partners is acting as sole bookrunning manager for the proposed
Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway
WOBURN, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that it has submitted a biologics license application (BLA) to the FDA for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of adult patients with advanced melanoma who have previously received an anti-PD1 containing regimen. The submission was made under the Accelerated Approval pathway. The Company also announced that the FDA has granted Breakthrough Therapy designation to RP1 in combination with nivolumab in the same setting. Breakthrough Therapy designat
Replimune Group Inc. Analyst Ratings
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
ROTH MKM initiated coverage on Replimune with a new price target
ROTH MKM initiated coverage of Replimune with a rating of Buy and set a new price target of $17.00
Piper Sandler resumed coverage on Replimune with a new price target
Piper Sandler resumed coverage of Replimune with a rating of Overweight and set a new price target of $44.00
Piper Sandler initiated coverage on Replimune Group with a new price target
Piper Sandler initiated coverage of Replimune Group with a rating of Overweight and set a new price target of $52.00
BTIG Research resumed coverage on Replimune with a new price target
BTIG Research resumed coverage of Replimune with a rating of Buy and set a new price target of $60.00
SVB Leerink reiterated coverage on Replimune Group with a new price target
SVB Leerink reiterated coverage of Replimune Group with a rating of Outperform and set a new price target of $49.00 from $55.00 previously
SVB Leerink reiterated coverage on Replimune Group with a new price target
SVB Leerink reiterated coverage of Replimune Group with a rating of Outperform and set a new price target of $55.00 from $56.00 previously
HC Wainwright resumed coverage on Replimune Group with a new price target
HC Wainwright resumed coverage of Replimune Group with a rating of Buy and set a new price target of $60.00 from $58.00 previously
SVB Leerink reiterated coverage on Replimune Group with a new price target
SVB Leerink reiterated coverage of Replimune Group with a rating of Outperform and set a new price target of $56.00 from $57.00 previously
Replimune Group Inc. Insider Trading
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
SEC Form 3 filed by new insider Goller Michael
3 - Replimune Group, Inc. (0001737953) (Issuer)
SEC Form 4 filed by Director Baker Bros. Advisors Lp
4 - Replimune Group, Inc. (0001737953) (Issuer)
New insider Baker Bros. Advisors Lp claimed ownership of 11,045,336 shares (SEC Form 3)
3 - Replimune Group, Inc. (0001737953) (Issuer)
Chief Executive Officer Patel Sushil sold $124,200 worth of shares (10,000 units at $12.42), decreasing direct ownership by 5% to 202,014 units (SEC Form 4)
4 - Replimune Group, Inc. (0001737953) (Issuer)
Chief Medical Officer Xynos Konstantinos sold $78,112 worth of shares (7,246 units at $10.78), decreasing direct ownership by 6% to 109,885 units (SEC Form 4)
4 - Replimune Group, Inc. (0001737953) (Issuer)
Chief Commercial Officer Sarchi Christopher sold $56,131 worth of shares (5,207 units at $10.78), decreasing direct ownership by 6% to 87,045 units (SEC Form 4)
4 - Replimune Group, Inc. (0001737953) (Issuer)
SEC Form 4 filed by Director Balachandran Madhavan
4 - Replimune Group, Inc. (0001737953) (Issuer)
SEC Form 3 filed by new insider Balachandran Madhavan
3 - Replimune Group, Inc. (0001737953) (Issuer)
Executive Chairman Astley-Sparke Philip gifted 50,000 shares, decreasing direct ownership by 3% to 1,437,350 units (SEC Form 4)
4 - Replimune Group, Inc. (0001737953) (Issuer)
Chief Financial Officer Hill Emily Luisa sold $90,989 worth of shares (8,938 units at $10.18), decreasing direct ownership by 8% to 101,057 units (SEC Form 4)
4 - Replimune Group, Inc. (0001737953) (Issuer)
Replimune Group Inc. SEC Filings
SEC Form S-8 filed by Replimune Group Inc.
S-8 - Replimune Group, Inc. (0001737953) (Filer)
SEC Form SCHEDULE 13D filed by Replimune Group Inc.
SCHEDULE 13D - Replimune Group, Inc. (0001737953) (Subject)
Replimune Group Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits
8-K - Replimune Group, Inc. (0001737953) (Filer)
Amendment: SEC Form SCHEDULE 13G/A filed by Replimune Group Inc.
SCHEDULE 13G/A - Replimune Group, Inc. (0001737953) (Subject)
SEC Form S-8 filed by Replimune Group Inc.
S-8 - Replimune Group, Inc. (0001737953) (Filer)
SEC Form 10-Q filed by Replimune Group Inc.
10-Q - Replimune Group, Inc. (0001737953) (Filer)
Replimune Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - Replimune Group, Inc. (0001737953) (Filer)
Amendment: SEC Form SCHEDULE 13G/A filed by Replimune Group Inc.
SCHEDULE 13G/A - Replimune Group, Inc. (0001737953) (Subject)
Replimune Group Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - Replimune Group, Inc. (0001737953) (Filer)
SEC Form S-8 filed by Replimune Group Inc.
S-8 - Replimune Group, Inc. (0001737953) (Filer)
Replimune Group Inc. Leadership Updates
Live Leadership Updates
Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions
Philip Astley-Sparke to transition from current role of CEO to Executive Chairman Planned leadership changes position the Company for commercialization Preparations on track to submit RP1 biologics license application (BLA) in 2H 2024 WOBURN, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced changes to its executive leadership team designed to support the Company's preparations for the commercial launch of RP1, pending regulatory submission and approval in anti-PD1 failed melanoma. Sushil Patel, Ph.D., will succeed Philip
Tessellate BIO Emerges from Stealth
The company aims to become a global leader in precision oncology by redefining Synthetic Lethality to treat large, currently unserved patient populationsLead program targets Alternative Lengthening of Telomeres (ALT) through the FANCM protein complexCompany backed by leading venture firms, BioGeneration Ventures (BGV) and ForbionWorld-class leadership team with proven experience as entrepreneurs and deep expertise in drug discovery and precision oncology AMSTERDAM and LONDON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, has today emerged from stealth, with an initial €8m in s
Replimune Announces Appointment of Emily Hill as Chief Financial Officer
WOBURN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced the appointment of Emily Hill as Chief Financial Officer. Ms. Hill was most recently CFO of the commercial stage biotech company PTC Therapeutics and has more than 15 years of experience in the biotechnology and life sciences industry having held senior financial management and investor relations roles at several leading public biotechnology and pharmaceutical companies. "Emily brings a wealth of financial planning and strategy experience to Replimune that will be impactfu
Former CEO and Chairman of the Board of Bayer Pharma AG, Dieter Weinand, Joins Coya's Board of Directors
Mr. Weinand is the former CEO and Chairman of the Board at Bayer Pharma AG, leading Bayer's fully integrated $20 billion healthcare business Mr. Weinand is a seasoned business leader with over 25 years of experience leading business and strategic operations for companies including Bayer, Pfizer, Bristol Myers Squibb, Sanofi, and Otsuka Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced that it has appointed Mr. Dieter Weinand to its board of directors, effective immediately. Coya will leverage Mr. Weinand's extens
Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update
Topline data from the registration-directed CERPASS clinical trial of RP1 combined with Libtayo® (cemiplimab-rwlc) in cutaneous squamous cell carcinoma expected in early Q4 2023 and Biologics License Application submission anticipated in Q1/2 2024 Cost sharing collaboration in cutaneous squamous cell carcinoma in the neoadjuvant setting entered into with Incyte Data snapshot for all 141 patients in the IGNYTE clinical trial cohort of RP1 in anti-PD1 failed melanoma expected Q4 2023 RP2 and RP3 Phase 2 programs; third-line colorectal cancer clinical trial initiated, first- and second-line hepatocellular carcinoma trials expected to initiate this quarter; Phase 1 clinical trial
Replimune Appoints Veleka R. Peeples-Dyer to its Board of Directors
WOBURN, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced the appointment of Veleka R. Peeples-Dyer to the Company's Board of Directors effective June 1, 2023. "We are pleased to welcome Veleka to Replimune's Board of Directors," said Philip Astley-Sparke, Chief Executive Officer of Replimune. "Veleka is a highly accomplished life sciences executive, experienced attorney and compliance professional with over 24 years of her practice dedicated to the life sciences industry assisting with building legal and compliance
Forbion appoints Silva Deželan, PhD as Head of Impact and ESG
NAARDEN, Netherlands and MUNICH, Germany, May 04, 2023 (GLOBE NEWSWIRE) -- Forbion, a leading European life sciences venture capital firm, announces the appointment of Silva Deželan PhD, as Forbion's first Head of Impact & ESG. Silva has over 15 years of experience in ESG integration, sustainability and impact investing, including private equity, most recently as ESG Director at Stafford Capital Partners and before that as Director, Sustainability, Private Equity at Robeco. Silva contributes her knowledge of ESG best-practice to a number of professional organizations, including as vice-chair of Invest Europe's ESG Committee, and as a member of the Responsible Investment Committee of the Du
Replimune Appoints Former Sanofi U.S. Commercial Oncology Head, Chris Sarchi, as Chief Commercial Officer and Sushil Patel as Chief Strategy Officer
WOBURN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies (TDOIs), announced today the appointment of Christopher Sarchi as Replimune's Chief Commercial Officer and the appointment of Sushil Patel, Ph.D., previously Replimune's Chief Commercial Officer, to a newly created position of Chief Strategy Officer, effective immediately. "These leadership appointments provide broad strategic and operational commercial acumen as we ramp up our commercial planning ahead of the potential 2024 commercial launch of RP1," said Philip Astley-Sparke, C
Replimune Appoints Christy Oliger to its Board of Directors
WOBURN, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a biotechnology company developing a range of product candidates derived from its oncolytic immuno-gene therapy platform, today announced the appointment of Christy Oliger to the Company's Board of Directors effective December 1, 2021. "We are delighted to welcome Christy to Replimune's Board of Directors," said Philip Astley-Sparke, Chief Executive Officer of Replimune. "Christy brings nearly 30 years of commercial and business experience in the pharmaceutical and biotechnology industry foremostly in oncology. We look forward to working with Christy and believe her guidance and input will strengthen our
Replimune Appoints Tanya Lewis as Chief Development Operations Officer
WOBURN, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced the strengthening of its executive team with the appointment of Tanya Lewis to a newly created position of Chief Development Operations Officer effective May 10, 2021. Ms. Lewis previously served on Replimune's board of directors and resigned on May 7th in order to join the executive team. Ms. Lewis joins from Karyopharm Therapeutics, a publicly traded biopharmaceutical company, where she served as Executive Vice President, Chief Regulatory Strategy and Strategic Operations Officer and
Replimune Group Inc. Financials
Live finance-specific insights
Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma
Primary endpoint data shows 12-month overall response rate (ORR) of 33.6% Biologics license application (BLA) submission intended for 2H 2024; first patient expected to be enrolled in IGNYTE-3 confirmatory trial in Q3 2024 Company to host conference call and webcast today at 8:00 a.m. ET WOBURN, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced the topline results from the primary analysis of the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma. The results by independent central review show one-third of pat
Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers
RP1 in combination with cemiplimab demonstrated clinically meaningful improvements in complete response rate and duration of response compared to cemiplimab in the CERPASS clinical trial, but did not meet either of the two primary endpoints Positive data update for full 140 patients in the IGNYTE clinical trial cohort of RP1 in anti-PD1 failed melanoma reinforces durable benefit; biologics license application (BLA) submission planned for 2H 2024 RP1 monotherapy data from ARTACUS clinical trial and new data from first 30 patients with anti-PD1 failed non-melanoma skin cancers in IGNYTE trial adds to growing body of evidence supporting the potential of RP1 in difficult to treat skin cancer s
Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update
The Company plans to hold a conference call in early December to provide a comprehensive RP1 skin cancer program update including: Topline data from the CERPASS clinical trial of RP1 combined with Libtayo in cutaneous squamous cell carcinomaAn initial data snapshot for all 140 patients in the IGNYTE clinical trial cohort of RP1 in anti-PD1 failed melanomaInitial data from the IGNYTE cohort of RP1 in anti-PD1 failed non-melanoma skin cancersA recap of interim data from the ARTACUS clinical trial of RP1 monotherapy in solid organ transplant recipients with skin cancer recently presented at SITC 2023 WOBURN, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:
Replimune Group Inc. Large Ownership Changes
This live feed shows all institutional transactions in real time.
Amendment: SEC Form SC 13G/A filed by Replimune Group Inc.
SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)
Amendment: SEC Form SC 13G/A filed by Replimune Group Inc.
SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)
Amendment: SEC Form SC 13G/A filed by Replimune Group Inc.
SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)
Amendment: SEC Form SC 13G/A filed by Replimune Group Inc.
SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)
Amendment: SEC Form SC 13G/A filed by Replimune Group Inc.
SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)
Amendment: SEC Form SC 13G/A filed by Replimune Group Inc.
SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)
Amendment: SEC Form SC 13G/A filed by Replimune Group Inc.
SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)
Amendment: SEC Form SC 13G/A filed by Replimune Group Inc.
SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)
SEC Form SC 13G/A filed by Replimune Group Inc. (Amendment)
SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)
SEC Form SC 13G/A filed by Replimune Group Inc. (Amendment)
SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)